ArticleJCO clinical cancer informatics2025
Deep Learning Model for Natural Language to Assess Effectiveness of Patients With Non-Muscle Invasive Bladder Cancer Receiving Intravesical Bacillus Calmette-Guérin Therapy.
Article in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.Translational andrology and urology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCollecting information on clinical outcomes (recurrence/progression) from complex treatment courses in non-muscle invasive bladder cancer (NMIBC) is challenging and time-consuming. We developed a deep learning natural language processing model to assess outcomes in patients with NMIBC using vast data from electronic health records (EHRs).
methodsThis retrospective study analyzed data from Japanese adults with NMIBC who started Bacillus Calmette-Guérin (BCG) induction therapy between April 2016 and June 2022. A Bidirectional Encoder Representations from Transformers (BERT) model was trained to classify outcomes, supported by human review for past history records. The model's performance was assessed by precision, recall, and F1 scores. We compared the effectiveness of BCG therapy between completion (patients who completed therapy) and non-completion groups.
resultsOf 372 patients studied, 79.3% and 20.7% were in the completion group and the non-completion group, respectively. The final BERT model achieved average F1 scores of 0.91 and 0.98 for time to recurrence (TTR), and 0.74 and 0.94 for time to progression (TTP) before and after human support, respectively. The hazard ratio for TTR in BCG completion versus non-completion groups was 0.40 (95% CI, 0.26 to 0.62) by a multivariate Cox proportional hazard model and 0.41 (95% CI, 0.26 to 0.63) by inverse probability of treatment weighting.
conclusionThe developed model could compare the clinical outcomes between treatments in patients with NMIBC using EHRs. Human support, although required, was needed in only 10% documents and was deemed feasible. The model was able to demonstrate the difference in TTR and TTP between BCG completion and non-completion groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.